Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ENZY

(ENZY) (ENZY) Stock Price, News & Analysis

(ENZY) logo

About (ENZY) Stock (NASDAQ:ENZY)

Advanced Chart

Key Stats

Today's Range
$11.85
$11.85
50-Day Range
N/A
52-Week Range
$6.30
$12.35
Volume
N/A
Average Volume
120,557 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company's technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company's segments offer a range of products that leverage its lipid-related offerings. Its product suite addresses the entire human life-cycle, from infancy to old age, and comprises ingredients in products ranging from infant formula to nutritional supplements, as well as branded medical foods, sold only under a doctor's supervision. It markets its product portfolio to established global consumer companies and physicians and target large and growing consumer health and wellness markets. The Company's clinically-validated products include bio-functional lipid-based compounds designed to address dietary needs, medical disorders and common diseases.

Receive ENZY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (ENZY) and its competitors with MarketBeat's FREE daily newsletter.

ENZY Stock News Headlines

Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.
See More Headlines

ENZY Stock Analysis - Frequently Asked Questions

(ENZY) (NASDAQ:ENZY) issued its earnings results on Wednesday, May, 17th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by $0.03. The company's revenue was down 14.3% on a year-over-year basis.

Based on aggregate information from My MarketBeat watchlists, some other companies that (ENZY) investors own include Caesarstone (CSTE), Laredo Petroleum (LPI), Allena Pharmaceuticals (ALNA), Camtek (CAMT), Arbutus Biopharma (ABUS), Ampliphi Biosciences (APHB) and Aquinox Pharmaceuticals (AQXP).

Company Calendar

Last Earnings
5/17/2017
Today
5/13/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:ENZY
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:ENZY) was last updated on 5/14/2025 by MarketBeat.com Staff
From Our Partners